JP2012224636A5 - - Google Patents

Download PDF

Info

Publication number
JP2012224636A5
JP2012224636A5 JP2012166700A JP2012166700A JP2012224636A5 JP 2012224636 A5 JP2012224636 A5 JP 2012224636A5 JP 2012166700 A JP2012166700 A JP 2012166700A JP 2012166700 A JP2012166700 A JP 2012166700A JP 2012224636 A5 JP2012224636 A5 JP 2012224636A5
Authority
JP
Japan
Prior art keywords
glucan
conjugate according
conjugate
laminarin
bacterial toxoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012166700A
Other languages
English (en)
Japanese (ja)
Other versions
JP5684758B2 (ja
JP2012224636A (ja
Filing date
Publication date
Priority claimed from GBGB0211118.5A external-priority patent/GB0211118D0/en
Application filed filed Critical
Publication of JP2012224636A publication Critical patent/JP2012224636A/ja
Publication of JP2012224636A5 publication Critical patent/JP2012224636A5/ja
Application granted granted Critical
Publication of JP5684758B2 publication Critical patent/JP5684758B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2012166700A 2002-05-15 2012-07-27 グルカンベースのワクチン Expired - Fee Related JP5684758B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0211118.5A GB0211118D0 (en) 2002-05-15 2002-05-15 Vaccines
GB0211118.5 2002-05-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2009294467A Division JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン

Publications (3)

Publication Number Publication Date
JP2012224636A JP2012224636A (ja) 2012-11-15
JP2012224636A5 true JP2012224636A5 (enExample) 2013-07-18
JP5684758B2 JP5684758B2 (ja) 2015-03-18

Family

ID=9936711

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004505087A Expired - Fee Related JP5110767B2 (ja) 2002-05-15 2003-05-15 グルカンベースのワクチン
JP2009294467A Pending JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン
JP2012166700A Expired - Fee Related JP5684758B2 (ja) 2002-05-15 2012-07-27 グルカンベースのワクチン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2004505087A Expired - Fee Related JP5110767B2 (ja) 2002-05-15 2003-05-15 グルカンベースのワクチン
JP2009294467A Pending JP2010131017A (ja) 2002-05-15 2009-12-25 グルカンベースのワクチン

Country Status (14)

Country Link
US (4) US20050208079A1 (enExample)
EP (2) EP1506009B1 (enExample)
JP (3) JP5110767B2 (enExample)
AT (2) ATE395080T1 (enExample)
AU (1) AU2003241104A1 (enExample)
CA (2) CA2485847C (enExample)
CY (1) CY1108234T1 (enExample)
DE (2) DE60336027D1 (enExample)
DK (1) DK1506009T3 (enExample)
ES (1) ES2306871T3 (enExample)
GB (1) GB0211118D0 (enExample)
PT (1) PT1506009E (enExample)
SI (1) SI1506009T1 (enExample)
WO (1) WO2003097091A2 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US8071552B2 (en) * 2004-04-05 2011-12-06 Universite Bordeaux 2 Peptides and peptidomimetics binding to CD23
GB0420466D0 (en) 2004-09-14 2004-10-20 Cassone Antonio Anti-glucan antibodies
PE20110072A1 (es) * 2005-06-27 2011-02-04 Glaxosmithkline Biolog Sa Composicion inmunogenica
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
WO2007127668A2 (en) * 2006-04-26 2007-11-08 Wyeth Novel processes for coating container means which inhibit precipitation of polysaccharide-protein conjugate formulations
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
AU2013203785B2 (en) * 2006-11-06 2016-11-17 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
JP4687644B2 (ja) 2006-12-22 2011-05-25 富士ゼロックス株式会社 画像処理装置、画像読取装置及び画像形成装置
US20100266626A1 (en) * 2007-11-26 2010-10-21 Francesco Berti Adjuvanted glucans
CA2706620C (en) 2007-11-26 2018-02-27 Novartis Ag Conjugated beta-1,3-linked glucans
JP2011519049A (ja) 2008-04-29 2011-06-30 イミューンエクサイト インコーポレイテッド 免疫調節組成物およびその使用方法
WO2010032138A2 (en) 2008-09-18 2010-03-25 Novartis Ag Vaccine adjuvant combinations
NL1036661C2 (en) 2009-03-04 2010-09-07 Serrix B V Anti-fungal compounds & compositions.
CN102438632A (zh) * 2009-03-10 2012-05-02 帕尔梅德特瓦有限公司 新颖的毛头鬼伞和黄金银耳蘑菇菌株及其产物和提取物以及包含它们的组合物
EP2470205A1 (en) 2009-08-27 2012-07-04 Novartis AG Adjuvant comprising aluminium, oligonucleotide and polycation
WO2011027222A2 (en) 2009-09-02 2011-03-10 Novartis Ag Immunogenic compositions including tlr activity modulators
WO2011035205A2 (en) 2009-09-18 2011-03-24 Calmune Corporation Antibodies against candida, collections thereof and methods of use
RS57937B1 (sr) * 2010-05-14 2019-01-31 Alltech Inc Komponente ćelijskog zida kvasca i njihova detekcija
AU2011295853A1 (en) 2010-09-01 2013-04-04 Irm Llc Adsorption of immunopotentiators to insoluble metal salts
ES2630029T3 (es) 2010-12-14 2017-08-17 Glaxosmithkline Biologicals Sa Análisis de citometría de flujo de materiales adsorbidos en sales metálicas
WO2012117377A1 (en) 2011-03-02 2012-09-07 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
EP2729178A1 (en) 2011-07-08 2014-05-14 Novartis AG Tyrosine ligation process
RU2636350C2 (ru) 2011-11-07 2017-11-22 Новартис Аг МОЛЕКУЛА, СОДЕРЖАЩАЯ SPR0096 и SPR2021
SI2822947T1 (sl) 2012-03-07 2016-10-28 Glaxosmithkline Biologicals S.A. Argininske soli TLR7 agonista
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Streptococcuspneumoniae抗原の増強された製剤
MX372965B (es) 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
EP3363462A1 (en) 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
BR112015018014A2 (pt) 2013-02-01 2017-07-11 Glaxosmithkline Biologicals Sa liberação intradérmica de composições imunológicas compreendendo agonistas do receptor do tipo toll
CN103083663B (zh) * 2013-02-04 2014-12-10 江苏省农业科学院 一种免疫增强剂、灭活疫苗及其制备方法
WO2014158963A1 (en) * 2013-03-12 2014-10-02 Wellstat Vaccines, Llc Antibodies targeted to fungal cell wall polysaccharides
AU2014286990A1 (en) 2013-07-11 2016-02-11 Novartis Ag Lysine-specific chemoenzymatic protein modifications using microbial transglutaminase
MX2016007148A (es) * 2013-12-05 2016-12-07 Biothera Inc Metodos de ensayo de beta-glucano.
PT3071235T (pt) * 2015-01-26 2018-02-21 Kaleido Biosciences Inc Produtos terapêuticos de glicanos e respetivos métodos relacionados
CN104771498A (zh) * 2015-03-13 2015-07-15 臧海阳 一种治疗热毒蕴结型痄腮的中药组合物
WO2018156888A1 (en) 2017-02-24 2018-08-30 Biothera Pharmaceuticals, Inc. Beta glucan immunopharmacodynamics
WO2019141774A1 (en) 2018-01-19 2019-07-25 Miltenyi Biotec Gmbh Regulatory t cell expressing a chimeric antigen receptor
US11701417B2 (en) * 2019-03-27 2023-07-18 West Virginia University Vaccine formulation to protect against pertussis
WO2023002252A1 (en) 2021-07-21 2023-01-26 Bioatlantis Limited Composition comprising beta-glucans and alpha-fucans for improving gut health and animal performance and methods of making the same
JP2025507875A (ja) 2022-02-28 2025-03-21 トライデム バイオサイエンス ゲーエムベーハー ウント コンパニー カーゲー 少なくともβ-グルカン若しくはマンナンからなるか、又はこれを含む結合体
EP4486389A1 (en) 2022-02-28 2025-01-08 Tridem Bioscience GmbH & Co KG A conjugate comprising at least a beta-glucan

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE466289B (sv) * 1984-09-19 1992-01-27 James Hoffman Makrofagstimulerande komposition jaemte foerfarande foer dess framstaellning
JPS6383012A (ja) * 1986-09-26 1988-04-13 Nonogawa Shoji:Kk 化粧料
JPH05503952A (ja) * 1989-09-08 1993-06-24 アルファ ベータ テクノロジー,インコーポレイティッド 可溶性グルカン類の製造方法
EP0471954A3 (en) * 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ATE280235T1 (de) * 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
CN1094288A (zh) * 1993-04-23 1994-11-02 福建省微生物研究所 利用红色诺卡氏菌制造细胞壁骨架粉末的方法
NO300692B1 (no) 1994-04-29 1997-07-07 Biotec Mackzymal As Solubilisert forgrenet ß-1,3-glukan og anvendelse derav samt anvendelse av usolubilisert forgrenet ß-1,3-glukan
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
JPH09309842A (ja) * 1996-05-20 1997-12-02 Kureha Chem Ind Co Ltd 新規な生理活性物質、その製造方法及び医薬組成物
US6573245B1 (en) * 1998-04-28 2003-06-03 Galenica Pharmaceuticals, Inc. Modified polysaccharide adjuvant-protein antigen conjugates, the preparation thereof and the use thereof
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4230635B2 (ja) 2000-02-29 2009-02-25 富士フイルム株式会社 デジタルカメラ

Similar Documents

Publication Publication Date Title
JP2012224636A5 (enExample)
WO2009039229A3 (en) Method of conferring a protective immune response to norovirus
MX342684B (es) Regimen de dosificacion escalante para efectuar la perdida de peso y el tratamiento de obesidad.
EP2762165A3 (en) Composition comprising a complexed (m)RNA and a naked mRNA for providing or enhancing an immunostimulatory response in a mammal and uses thereof
NO20083722L (no) Immunogen sammensetning
WO2009051837A3 (en) Vaccine nanotechnology
WO2009090670A3 (en) Stabilized sustained release composition of bupropion hydrochloride and process for preparing the same
JP2010215657A5 (enExample)
WO2011156774A3 (en) Multivalent glycopeptide constructs and uses thereof
WO2009077854A3 (en) Adjuvanted glucans
EP3064220A3 (en) Compositions and methods for the treatment of infections and tumors
MY165831A (en) Methods of reducing virucidal activity in pcv-2 compositions and pcv-2 compositions with a improved immunogenicity
WO2007105115A3 (en) Compositions and methods for immunisation using cd1d ligands
IL210789A (en) Susanimidyl 4-acetylsulfanyl butyrate, para-nitrophenyl 4-acetylsulfanyl butyrate, a method for synthesized oligosaccharide-bearing synthesis, an oligosaccharide-containing preparation, and an oligosaccharide-bore oligosaccharide pair
WO2006126981A3 (en) Compositions and methods for mucosal vaccination
WO2006030318A3 (en) PROTECTIVE ANTI-GLUCAN ANTIBODIES WITH PREFERENCE FOR β-1,3-GLUCANS
WO2007084661A3 (en) Therapy-enhancing glucan
WO2011060372A3 (en) Factor viii b cell epitope variants having reduced immunogenicity
MX2024013161A (es) Conjugado proteico de polisacarido inmunogenico que comprende un polisacarido derivado de estreptococo grupo b (gbs)
JP2008535798A5 (enExample)
JP2008525311A5 (enExample)
WO2008008541A8 (en) Methods to elicit, enhance and sustain immune responses against mhc class-i restricted epitopes, for prophylactic or therapeutic purposes
WO2011047837A3 (de) Schmelzgranuliertes cinacalcet
WO2007081896A3 (en) Pharmaceutical compositions and methods to vaccinate against disseminated candidiasis and other infectious agents
WO2009142988A3 (en) Chitin micro-particles as an adjuvant